XML 75 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Significant Concentrations (Details)
$ in Thousands
12 Months Ended
Feb. 17, 2014
Mar. 03, 2018
USD ($)
derivative
Mar. 04, 2017
USD ($)
derivative
Feb. 27, 2016
USD ($)
Derivatives        
Number of interest rate swap arrangements or other derivatives held | derivative   0 0  
Retail Pharmacy | Pharmacy sales | Customers | Top five third party payors        
Significant Concentrations        
Percentage of concentration risk   78.60%    
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Express Scripts        
Significant Concentrations        
Percentage of concentration risk     26.00% 27.10%
Retail Pharmacy | Pharmacy sales | Customers | Largest third party payor | Caremark        
Significant Concentrations        
Percentage of concentration risk   27.20%    
Retail Pharmacy | Pharmacy sales | Customers | Medicaid agencies and related managed care Medicaid payors        
Significant Concentrations        
Percentage of concentration risk   20.40%    
Retail Pharmacy | Pharmacy sales | Customers | Largest Medicaid agency        
Significant Concentrations        
Percentage of concentration risk   1.90%    
Retail Pharmacy | Pharmacy sales | Customers | Medicare Part D        
Significant Concentrations        
Percentage of concentration risk   34.10%    
Retail Pharmacy | Purchases | Suppliers | McKesson Corp.        
Significant Concentrations        
Percentage of concentration risk   97.80%    
Period for Purchasing and Delivery Arrangement 5 years      
Pharmacy Services | Medicare Part D        
Significant Concentrations        
Net revenues | $   $ 203,361 $ 223,077 $ 162,620
Percentage of revenues   1.00% 1.00% 0.80%
Pharmacy Services | Medicare Part D | Swiss Re        
Significant Concentrations        
Percentage of revenues   50.00%    
Percentage of cost of revenue   50.00%